Preloader
Get In Touch
Preloader

The Science

How MitoForge™ finds the right cell - and fixes the right defect

A modular, peptide-directed delivery system built to restore mitochondrial energy production at its source, paired with a stress-responsive, site-specific mechanism of action.

01

A precision-delivery platform, built in three parts

Every MitoForge conjugate shares the same underlying architecture – a tissue-directed targeting peptide, a proprietary linker, and a modular payload – so the platform can be redirected to new tissues and new mechanisms without rebuilding it from scratch.
3

Tissue-directed targeting peptide

Designed for preferential delivery to selected cells - the address label that determines which tissue the payload reaches.

Proprietary linker system

Engineered for stability in circulation, then controlled release of the payload once inside the target cell.

Modular payload

Supports both small-molecule and biologic payloads - the primary therapeutic mechanism - on the same delivery backbone.

02

Stress-responsive, site-specific bioenergetic activation

VTI-531’s mechanism of action preferentially restores ATP in energetically compromised tissue – through a dual pathway of AMPK activation and adenosine-regulating activity.
An AMP-mimetic, direct AMPK agonist derived from AICA riboside. AMPK is the master regulator of cellular energy homeostasis – it senses the balance between ATP depletion and AMP/ADP accumulation, then coordinates metabolic pathways to match nutrient supply with energy demand. In stressed myocardium, VTI-531 reprograms metabolism to reduce net ATP depletion, enhances ATP-generating pathways including glucose uptake and fatty-acid oxidation, and restores a favorable ADP:ATP balance.

Effect on myocardial performance

  • Improves left ventricular ejection fraction, without increasing heart rate
  • Without increasing blood pressure
  • Without increasing myocardial oxygen consumption (MVO₂)
  • Without causing arrhythmia
Source data on file; full mechanism-of-action references available on request. (The source presentation flagged this claim for a citation that hadn’t been added yet – carrying that forward rather than inventing one.)

AMPK activation

  • Senses the balance between ATP depletion and AMP/ADP accumulation
  • Coordinates metabolic pathways to match nutrient supply with energy demand
  • In stressed tissue, promotes bioenergetic recovery and metabolic efficiency

Adenosine regulation

  • Reprograms metabolism to reduce net ATP depletion
  • Restores a favorable ADP:ATP balance and cellular energy homeostasis
  • Supports recovery of mitochondrial metabolic function in dysfunctional myocardium

03

Modular conjugate architecture

Because the bioenergetic payload sits on a modular backbone, it can be combined with a complementary therapeutic mechanism – extending the platform beyond bioenergetics alone.

Anti-fibrotic mechanism

Pairs mitochondrial energy restoration with a complementary mechanism aimed at reducing fibrotic remodeling in affected tissue.

Anti-inflammatory mechanism

Combines the core bioenergetic effect with a mechanism targeting the inflammatory component of metabolic and cardiovascular disease.

Ischemia-modulating mechanism

Adds a mechanism aimed at ischemic tissue response, for indications where oxygen-supply mismatch compounds mitochondrial stress.

AMP-activated protein kinase (AMPK)

AMPK is the master regulator of cellular energy homeostasis. It:
• Senses the balance between ATP depletion and AMP/ADP accumulation
• Coordinates metabolic pathways to match nutrient supply with energy demand
•In stressed tissue, promotes bioenergetic recovery and metabolic efficiency through its activation

Effects of VTI531 on AMPK

VT11531 is an AMP-mimetic, direct AMPK agonist derived from AICA riboside. Its effects on AMPK activation include:
• Reprogramming metabolism to reduce net ATP depletion
• Enhancing ATP-generating pathways, including glucose uptake and fatty acid oxidation
• Restoring a favorable ADP: ATP balance and cellular energy homeostasis
• Supporting recovery of mitochondrial metabolic function in dysfunctional myocardium

01

A precision-delivery platform, built in three parts

Every MitoForge conjugate shares the same underlying architecture – a tissue-directed targeting peptide, a proprietary linker, and a modular payload – so the platform can be redirected to new tissues and new mechanisms without rebuilding it from scratch.
Patents Granted Over Past 8 Years
40
Pending Applications
8

Patent Portfolio and IP Strategy

IP protection is built in layers around the platform core – from the targeting chemistry itself out to the specific therapeutic applications built on top of it.

TARGETING PEPTIDE FAMILIES

• Issued and pending patent protection
• Tissue-directed delivery technologies
• Peptide variants and optimization strategies

CONJUGATE PLATFORM FAMILY

• Provisional patent application pending
• Selected conjugate compositions, linkers, and delivery architecture
• Therapeutic applications

VTI531-DERIVED NCE FAMILY

• Composition-of-matter patent applications pending
• Next-generation bioenergetic modulators
• AMPK / adenosine-regulation biology

MULTI-MECHANISM PAYLOAD STRATEGY

• Complementary anti-fibrotic mechanisms
• Complementary anti-inflammatory mechanisms
• Complementary ischemia-modulating mechanisms

COLLABORATIVE STRENGTH: Ongoing collaborations with leading acudemic and private research partners

A clinical-stage biopharmaceutical company developing MitoForge™, a precision intracellular delivery platform for mitochondrial metabolic dysfunction.

Quick Links

Office

ViCardia Therapeutics, Inc. 530 Bush Street, Suite 802 San Francisco, CA 94108

© 2026 ViCardia Therapeutics, Inc. All Rights Reserved.

MitoForge™ and Precision Intracellular Delivery™ are trademarks of ViCardia Therapeutics, Inc.

Powered by